Clinical trials: Birch Pollen Allergy
Birch Pollen Allergy
Safety, Tolerability And Pharmacodynamics of DM-101PX in Birch Pollen Allergy
Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of DM-101-PX compared to placebo in birch pollen allergic adults.
- Trial name
- UPSIT (NCT07898800)
- Testing
- DM-101PX
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Desentum Oy
Birch Pollen Allergy
Study of DM-101PX in Adults With Birch Pollen Allergy
Randomized, double-blind placebo-controlled phase 2 trial with the aim to investigate safety and efficacy of DM-101-PX in reducing allergic symptoms provoked by nasal allergen challenge in birch pollen allergic adults.
- Trial name
- BASIT (NCT07254871)
- Testing
- DM-101PX
- Where
- Canada
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Desentum Oy
Allergic Rhinoconjunctivitis, Birch Pollen Allergy
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma
Allergic rhinoconjunctivitis due to birch pollen is a seasonal problem which manifests as a combination of nasal symptoms (such as congestion, runny nose, sneezing, itching of the nose) and ocular symptoms (such as red, itchy and…
- Trial name
- YOBI (NCT05668390)
- Testing
- STALORAL® Birch 300 IR
- Where
- 62 sites in Austria, Bulgaria and 10 more
- Volunteers
- 553 people
- Sponsor
- Stallergenes Greer
House Dust Mite Allergy, Birch Pollen Allergy
Evaluation of an Adjusted Cutoff Value for S.P.A.T (Skin Prick Automated Test) Device in Allergic Subjects
Skin prick test (SPT) is a first line diagnostic test to detect type I hypersensitivity in patients suspected of an inhalant allergy. A novel S.P.A.T.
- Trial name
- SPATprovocatio (NCT06803953)
- Testing
- Skin Prick Automated Test, Skin Prick Manual Test, Nasal Allergen Challenge
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Hippocreates
Birch Pollen Allergy
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of three ascending dosing schemes of DM-101-PX in birch pollen allergic adults.
- Trial name
- NCT06037148
- Testing
- DM-101PX
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Desentum Oy
Birch Pollen Allergy
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
Randomized, double-blind placebo-controlled phase I study to investigate the safety and tolerability of ascending doses of DM-101 in adult subjects with birch pollen allergy.
- Trial name
- NCT04266028
- Testing
- DM-101
- Where
- Finland
- Volunteers
- 27 people
- Sponsor
- Desentum Oy
Birch Pollen Allergy, Grass Pollen Allergy
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
About 20% of the general population are affected by an allergy - with an upward trend. Quite often, allergic people do not consider their disease as serious and suffer from subsequent complications, like allergic asthma, later in…
- Conditions
- Birch Pollen Allergy, Grass Pollen Allergy, House Dust Mite Allergy, Cat Allergy
- Trial name
- MADMAX (NCT04435678)
- Testing
- ALEX² test using the MAX 45k automated laboratory system
- Where
- 2 sites in Austria
- Volunteers
- 839 people
- Sponsor
- MacroArray Diagnostics GmbH
Healthy Volunteers, Birch Pollen Allergy
Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants
The primary objective of the study is to evaluate the safety and tolerability of REGN5713-5714-5715 in healthy adult participants.
- Trial name
- NCT03969849
- Testing
- REGN5713-5714-5715
- Where
- 3 sites in Belgium
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Birch Pollen Allergy
Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment
Study aiming to evaluate the efficacy of a 2-month pre-seasonal treatment with an AllerT 50 µg or 100 µg maintenance dose administered in previous study AN004T in reducing symptoms of allergic rhinoconjunctivitis during the 2nd…
- Trial name
- NCT02143583
- Where
- 22 sites in Denmark, France and 5 more
- Volunteers
- 196 people
- Sponsor
- Anergis
Birch Pollen Allergy
A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet
The primary aim of this trial is to evaluate the dose-response relationship for the ALK tree AIT administered once daily in order to define a dose-range that would be suitable for at-home administration.
- Trial name
- NCT01675791
- Testing
- ALK tree AIT 0.5 DU, ALK tree AIT 1 DU, ALK tree AIT 2 DU
- Where
- 2 sites in Finland, Netherlands
- Volunteers
- 637 people
- Sponsor
- ALK-Abelló A/S
Birch Pollen Allergy
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis
Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis
- Trial name
- NCT00309062
- Testing
- Recombinant birch pollen
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Birch Pollen Allergy
Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV
Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV
- Trial name
- NCT00266526
- Testing
- Recombinant birch pollen
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Seasonal Rhinitis and/or Rhinoconjunctivitis, Birch Pollen Allergy
SUBLIVAC® Birch PROBE Study
Objective of the study is to show, on an exploratory basis, that treatment with SUBLIVAC Birch is also effective compared to treatment with Staloral Birch by means of reduction in allergic symptoms during nasal provocation in…
- Trial name
- NCT00932607
- Testing
- sublingual immunotherapy
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- HAL Allergy